Providence researcher in the news: a promising treatment for kidney disease

When Randy was diagnosed with small cell lung cancer, he thought it was time to get his affairs in order. But a phase I clinical trial at Providence Cancer Institute gave him more time and hope.

Research co-authored by Providence CARDS found striking disparities in off-label prescribing of the popular GLP1-RA medications initially FDA-approved for diabetes and more recently for weight loss

Two studies for people with ER+/HER2- breast cancer are enrolling patients at Providence Cancer Institute.

The annual AACR meeting draws the most innovative cancer researchers seeking breakthroughs in treatments.

Read about Dr. Lowenkopf’s storied 25-year career and his transformative work in stroke care, plus a personal message from Dr. Lowenkopf.

This is an exciting new trial comparing robotic assisted laparoscopy to open hysterectomy and lymph node assessment for the treatment of early-stage cervical cancer.

The Advancing Health Equity in Aging initiative aims to address disparities faced by older adults by harnessing interventions directly from their communities.  As the initiative's collaborative learni

The Truveta Genome Project will enable scientists to transform how diseases are prevented, diagnosed and cured.

The Oregon Health Authority has selected Providence CORE to evaluate the next phase of Oregon's ContraceptiveCare (CCare) program.

Discover how Dean Lookingbill’s battle with lymphoma led him to CAR T-cell therapy at Providence Cancer Institute.

Thanks in part to the work of gynecologic oncology researchers at Providence, healthcare providers and patients nationwide have a new standard of care for advanced or recurrent endometrial cancer.

Two global studies open at Providence Cancer Institute will evaluate combinations of medications to help stop or slow the growth of cancer in solid tumors.

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Learn about dysautonomia, its symptoms, and how it's connected to long COVID. Discover treatment options and expert insights at Providence.